Hypolipidemic and Hepatoprotective Effects of Myricitrin and Solid Lipid Nanoparticle-containing Myricitrin on the Male Mouse Model with Type 2 Diabetes Induced by Streptozotocin-Nicotinamide

Type 2 diabetes mellitus (T2DM) has several complications such as hyperlipidemia and hepatotoxicity. Myricitrin has an antidiabetic action along with low bioavailability. So, the aim of the present study was to investigate hypolipidemic and hepatoprotective effects of myricitrin and solid lipid nanoparticle (SLN) containing myricitrin on the T2DM mouse model induced by Streptozotocin-nicotinamide (STZ-NA).

In this experimental study, 90 Naval Medical Research Institute (NMRI) adult male mice were divided into 9 groups (n=10 per group): control, vehicle, diabetic, diabetic + myricitrin, or SLN containing myricitrin 1, 3, and 10 mg/kg groups. The cold homogenization method was used to prepare SLN containing myricitrin. The diabetic model was induced by one injection of STZ-NA (65-120 mg/kg) with a 15-min interval. Animals' treatment was done for 4 weeks. At the end of the experiment, plasma samples were taken for experimental assessments.

Plasma level of triglyceride (TG), low-density lipoprotein (LDL-C), very-low-density lipoprotein (VLDL), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) increased and high-density lipoprotein cholesterol (HDL-C) decreased in diabetic mice compared to the control group (P<0.05). Administration of myricitrin or SLN containing myricitrin decreased plasma levels of TG, LDL-C, VLDL, AST, and ALT and increased HDL-C in the treated diabetic groups compared to the untreated groups (P<0.05).

According to the results, myricitrin and SLN containing myricitrin showed hypolipidemic and hepatoprotective effects in T2DM mice. Also, SLN containing myricitrin was more potent than myricitrin especially in a low dose of administration.